Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

Can-Fite advances Namodenoson in HCC and pancreatic cancer; psoriasis interim readout expected in 2027

Sep 8, 2026, 8:31 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive signals from longer OS in HCC, durable pancreatic outcomes, and near-term psoriasis interim readout alongside warrant-driven funding can improve sentiment and support a re-rating, especially if interim results align with expectations.

AI summary

What happened, with direct paths to the underlying reporting

Can-Fite reported H1 2026 results alongside notable clinical progress across Namodenoson and Piclidenoson programs. Pancreatic cancer data show durable overall survival in a small, heavily pretreated cohort, while HCC signals suggest longer-than-expected survival, prompting an earlier interim analysis. Psoriasis enrollment reached 247 with an interim readout anticipated in Q1 2027, supported by IP gains and a warrant-driven liquidity boost.

H1 2026 revenues $0.20m; net loss $4.60m.
Pancreatic cancer Namodenoson Phase 2a: 20 patients, durable OS.
HCC Phase III: longer-than-expected OS; interim timing under review.
Psoriasis Phase 3 interim results planned Q1 2027 after 247 enroll.
September 2026 warrant proceeds ~$4.0m; cash and investments ~7.0m.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.